Sutureless Valve Held Largest Share of Product Segment in Aortic Valve Replacement Devices Market

According to our new research study on "Aortic Valve Replacement Devices Market Forecast to 2030 – COVID-19 Impact and Global Analysis – by Product, Surgery, End User," the market was valued at US$ 7,113.39 million in 2022 and is expected to reach US$ 18,070.32 million by 2030. It is estimated to register a CAGR of 12.4% during 2022–2030.

An aortic valve replacement involves removing a poorly working or damaged valve and replacing it with a new valve made from synthetic materials or animal tissue. The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.
A few technological advancements by the players in the aortic valve replacement devices are mentioned below:

• In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.
• In September 2022, Medtronic announced the expansion of its newest-generation, self-expanding TAVR system—the Evolut FX TAVR system—in the US. Evolut FX added new features to the existing Evolut platform to enhance the ease of use and predictable valve deployment for physicians.
• In September 2022, Edwards Lifesciences launched SAPIEN 3 Ultra RESILIA valve, which includes Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve. The launch follows recent US Food and Drug Administration (FDA) approval.
• In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
• In August 2021, CORCYM enrolled the first patient in the mitral, aortic, and tricuspid post-market study in a real-world setting, i.e., MANTRA. The first implantation was performed at Citta di Lecce Hospital in Italy with a Bicarbon aortic mechanical valve.
• In August 2021, the first Made in India 3D printed heart valve was developed in Chennai. The new heart valves were developed using 3D printers, which could overcome the problems related to artificial heart valves.
• In September 2020, Boston Scientific Corporation introduced the ACURATE neo2 aortic valve system in Europe. This next-generation TAVI technology—a new platform designed with multiple features to improve the clinical performance of the original ACURATE neo platform—had an expanded indication for patients with aortic stenosis compared to the aortic valve system of the previous generation.

Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.

Based on surgery, the aortic valve replacement devices market is divided open surgery and minimally invasive surgery. The minimally invasive surgery segment held a larger market share in 2022 and same segment is anticipated to register a highest CAGR during the forecast period. Minimally invasive surgery for aortic valve replacement is a less invasive approach compared to traditional open surgery. It involves making smaller incisions, often using specialized surgical instruments and video-assisted technology, to access the heart to replace a poorly working aortic valve with an artificial valve, either a mechanical valve or a bioprosthetic valve. The potential benefits of minimally invasive techniques include shorter hospital stays, reduced scarring, and faster recovery times (in normal conditions). As medical technology continues to advance, these minimally invasive approaches are offering more options and improved outcomes for patients requiring aortic valve replacement.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd, Artivion Inc, JenaValve Technology Inc., Venus MedTech HangZhou Inc., and Labcor Laboratorios Ltda. These players focus on expanding and diversifying their market presence and acquiring a novel customer base, tapping prevailing business opportunities in the aortic valve replacement devices.

The report segments the global aortic valve replacement devices market as follows:

The aortic valve replacement devices market is segmented based on product, surgery, and end user. By product, the aortic valve replacement devices market is segmented Sutureless Valve and Mechanical Valve. In terms of surgery, the aortic valve replacement devices market is divided into Minimally Invasive Surgery and Open Surgery. Based on end user, the aortic valve replacement devices market is bifurcated into hospitals & clinics, ambulatory surgical centers and others. Geographically, the aortic valve replacement devices market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com